CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES
SJIF Impact Factor: 7.187
https://doi.org/10.5281/zenodo.19737253

Available online at: http://www.iajps.com Review Article

3D PRINTING TECHNOLOGIES USED IN PHARMA

Ms. Shinde Amruta Nilesh and Miss. Shirke S.S
B.pharm final year, MSS's College of pharmacy, Medha

Abstract::
Three-dimensional (3D) printing has emerged as a transformative manufacturing technology in the pharmaceutical field, enabling the production of personalized, precise, and complex drug dosage forms. Various 3D printing techniques— including fused deposition modeling (FDM), stereolithography (SLA), selective laser sintering (SLS), inkjet printing, binder jetting, and semi-solid extrusion— allow controlled deposition of materials to fabricate patient-specific medicines with tailored dose, release kinetics, and geometry. These techniques support innovations such as polypills, rapid-dissolving tablets, modified-release systems, and implants. The first FDA-approved 3D-printed drug, Spritam®, demonstrated the clinical relevance of this technology. Advantages include on-demand manufacturing, high customization, and improved therapeutic outcomes. However, challenges such as limited pharmaceutical-grade printable materials, regulatory uncertainties, scale-up issues, and quality-control requirements continue to restrict widespread adoption. Overall, 3D printing represents a promising platform for advancing personalized medicine and redefining pharmaceutical manufacturing.

Keywords :-3D printing, Additive manufacturing, Personalized medicine, Fused deposition modeling (FDM), Stereolithography (SLA), Digital light processing (DLP), Selective laser sintering (SLS), Inkjet printing, Binder jetting, Semi-solid extrusion.

Corresponding author:
Amruta Nilesh Shinde,
MSS's College of pharmacy, Medha
B.pharm final year
Email I'd: amrutashindeas02@gmail.com
Phone number : 8421752862
Corresponding author : Ms. Shinde Amruta
Miss. Shirke S.S

QR CODE

Please cite this article in press Amruta Nilesh Shinde et al., 3D Printing Technologies Used In Pharma., Indo Am. J. P. Sci, 2026; 13(04).

INTRODUCTION:

Three-dimensional (3D) printing, also referred to as additive manufacturing, has emerged as one of the most transformative technologies in pharmaceutical sciences [1–3]. Unlike conventional "subtractive" manufacturing processes, 3D printing constructs objects layer by layer directly from computer-aided design (CAD) models, allowing exceptional precision and structural customization [2,3]. Since its invention by Charles Hull in 1986 through stereolithography (SLA), additive manufacturing has expanded rapidly across scientific and industrial sectors [1].

Over the past decade, 3D printing has increasingly influenced the pharmaceutical development continuum from preclinical formulation design and clinical trial material production to personalized dosing at the point of care [4,5]. A wide range of pharmaceutical dosage forms, including immediate-release and controlled- release tablets, micro-pills, microchips, implants, fast-disintegrating systems, microneedles, transdermal patches, and multiphase release formulations, has been successfully fabricated using various 3D printing techniques [4,6,7].

Compared with traditional manufacturing processes, 3D printing offers several advantages: rapid prototyping, high drug-loading capacity, reduced material wastage, and superior precision in dose design [4,6,7]. These advantages are particularly beneficial for producing dosage forms containing potent drugs, poorly water-soluble drugs, protein-based therapeutics, and narrow-therapeutic- index compounds [6–8].

Furthermore, advances in 3D printing have enabled fine control over microstructure, porosity, and surface characteristics of drug-delivery systems, leading to customizable release profiles and improved performance [7,8]. To standardize the rapidly evolving field, the American Society for Testing and Materials (ASTM) classifies 3D printing technologies into seven categories: material extrusion, binder jetting, powder bed fusion, vat photopolymerization, material jetting, directed energy deposition, and sheet lamination [9]. Among these, fused deposition modeling (FDM), semisolid extrusion (SSE), melt extrusion deposition (MED), binder jetting (BJ-3DP), and stereolithography (SLA) hold the greatest relevance in pharmaceutical research [6–8].

The increasing global emphasis on personalized medicine has further accelerated interest in 3D printing for individualized therapies [10,11]. Initiatives such as the
U.S. Precision Medicine Initiative and the UK Genome Strategy advocate transitioning from fixed-dose, mass-produced medicines toward personalized formulations tailored to an individual's genetics, physiology, lifestyle, and disease profile [10–12]. Personalized dosage forms whether dose-adjusted tablets, polypills, or patient-specific release systems have demonstrated significant potential to improve adherence, reduce adverse drug reactions, and enhance therapeutic outcomes [11–13].

As the demand for individualized therapies grows, 3D printing offers a flexible and powerful platform for on-demand manufacturing of patient-specific dosage forms. This review discusses current 3D printing technologies used in pharmaceuticals, their applications, advantages, limitations, and their emerging role in advancing personalized medicine [6–13].

HISTORICAL BACKGROUND:

The origins of three-dimensional (3D) printing trace back to the early 1980s, when additive manufacturing (AM) technologies were first conceptualized as a means to fabricate complex geometries through layer-by-layer deposition. In 1984, Charles Hull invented stereolithography (SLA), considered the first commercial 3D printing technique, marking a major breakthrough in rapid prototyping and automated manufacturing processes (1). Throughout the 1990s, advancements in computer-aided design (CAD), polymer chemistry, and laser systems facilitated the expansion of AM technologies into biomedical engineering, enabling the production of anatomical models, surgical tools, and implantable devices(6).

The application of 3D printing to pharmaceuticals emerged in the early 2000s, when researchers began exploring its potential for fabricating oral dosage forms with complex internal architectures and controlled drug-release profiles. Material extrusion techniques such as fused deposition modeling (FDM) and semisolid extrusion (SSE) enabled drug incorporation into polymeric matrices, while binder jetting and stereolithography allowed the fabrication of porous, fast-dissolving structures(4,5).

A landmark event occurred in 2015, when the U.S. Food and Drug Administration (FDA) approved the first 3D-printed drug product, Spritam® (levetiracetam), produced using binder jetting technology. This approval demonstrated the regulatory feasibility of 3D-printed pharmaceuticals and accelerated global research in the field(14).

In the 2020s, the integration of genomics, precision medicine initiatives, and point-of-care manufacturing has further expanded the role of 3D

printing in personalized drug delivery. Modern 3D printing systems now enable dose customization, multi-drug combinations, rapid prototyping, and advanced control over microstructure, positioning 3D printing as a transformative platform for future pharmaceutical manufacturing(6,13).

OBJECTIVES:

The primary objectives of this review are:

1. To provide a comprehensive historical and scientific overview of the evolution of 3D printing technologies and their transition into pharmaceutical applications(1,4,5,6).
2. To critically analyze major 3D printing technologies (e.g., FDM, SSE, MED, BJ-3DP, SLA) with emphasis on their working principles, material requirements, process parameters, and suitability for various pharmaceutical dosage forms(6,13).
3. To evaluate the influence of surface and interfacial characteristics of 3D- printed materials on drug release, mechanical performance, stability, and therapeutic outcomes(13).
4. To compare the advantages and limitations of each 3D printing technique in pharmaceutical development, manufacturing, and personalized medicine(6,13).
5. To assess the current industrial landscape of pharmaceutical 3D printing, including regulatory progress, commercial applications, challenges, and barriers to industrialization(6,14).
6. To identify future perspectives and research opportunities, including integration with artificial intelligence, point-of-care printing, novel printable materials, and emerging regulatory frameworks(13).

PRINCIPLE OF 3D PRINTING IN PHARMA:

3D printing in pharmaceuticals is based on the principle of additive manufacturing, where drug-loaded materials are deposited layer by layer to create a solid dosage form with precise geometry and controlled drug release (6).

The process begins with a digital 3D model designed using CAD software, which guides the printer in the spatial placement of each layer (7).

During printing, the formulation material (polymer, powder, resin, or semi-solid paste) is selectively deposited or solidified according to the digital blueprint (15).

Each printed layer is fused, sintered, cured, or bound to the previous one using heat (FDM), light (SLA), laser energy (SLS), or binder solutions (binder jetting) (16).

This layer-wise fabrication allows accurate control over shape, porosity, internal channels, drug loading, and release kinetics (17).

The principle enables production of personalized medicines such as customized dosage strengths, multi-drug tablets, fast-disintegrating structures, and modified- release systems (18).

Thus, 3D printing applies a controlled, automated, additive mechanism to build drug-containing structures with high precision, flexibility, and reproducibility (19).



Figure 1:- Principal of 3D printing in Pharma (6,7,15,16,17,18,19)

ADDITIVE MANUFACTURING TECHNOLOGIES USED IN PHARMACEUTICS:

1.FUSED DEPOSITION MODELING (FDM) :-

Fused Deposition Modeling (FDM) is an additive manufacturing (3D-printing) technology in which a thermoplastic polymer filament is melted and deposited layer-by-layer to form a solid dosage form or medical device(21).

It is one of the most widely studied 3D-printing methods in pharmaceutical manufacturing, especially for personalized medicines, controlled-release tablets, flexible doses, and polypills(20).

❖ **Working Principle**

1) Filament Preparation :-
A drug-loaded polymer filament is prepared using Hot-Melt Extrusion (HME)(24). Common pharmaceutical-grade polymers:
- PVA (Polyvinyl alcohol)
- Eudragit® polymers
- PLA, PCL, PEG-based materials(20).

The drug is uniformly dispersed in the molten polymer during extrusion(23).

2) Feeding of Filament
The filament spool is placed on the printer(21).
A gear-driven feeder pushes the filament into a heated nozzle(24).

3) Melting & Extrusion
The nozzle (extruder) heats the filament to a temperature slightly above its glass transition or melting point (normally 150–220 °C depending on polymer)(20).
The softened filament is extruded as a thin molten strand(21).

4) Layer-by-Layer Deposition
The nozzle moves in X–Y directions, depositing molten material according to the digital design (CAD model)(23).
After one layer is completed, the build platform lowers (Z-axis) and the next layer is deposited(22).
This continues until the final 3D object (tablet, implant, scaffold, or device) is formed(21).

5) Solidification
The extruded material solidifies quickly after deposition(20).
The final printed product has a layered internal structure, allowing control of:
- Porosity
- Release profile
- Shape and dose(22)

❖ **Advantages of FDM in Pharmaceuticals**
- Personalized dosing (individual strength tablets)(21).
- Complex internal geometries for modified/controlled release(20).
- Polypills (multiple drugs in one tablet)(23).
- Rapid prototyping of dosage forms(22).
- No use of toxic solvents(24).

❖ **Limitations**
- High processing temperature → heat-sensitive drugs may degrade(22).
- Need for printable filaments → limited polymer choices(20).
- Layer lines may affect mechanical strength(21).



Figure 2 :- Fused Deposition Modeling (21).

2. STEREOLITHOGRAPHY (SLA)AND DIGITAL LIGHT PROCESSING:

1. Stereolithography (SLA):-

Stereolithography (SLA) is a vat-photopolymerization 3D-printing technology in which a UV laser selectively cures a photosensitive liquid resin layer by layer to build a solid 3D object(8,25,18). A CAD model is digitally sliced into thin layers, and each layer is scanned by a laser beam to induce photopolymerization, converting liquid resin into a solid polymer network(8,26). After one layer is cured, the build platform moves, allowing a fresh layer of resin to coat the previous one. This process is repeated until the final structure is completed(25,27).



Figure 3:-Stereolithography (SLA)(33)

SLA is known for very high resolution, excellent surface finish, and the ability to fabricate complex geometries(8,18,27). In pharmaceuticals, it is applied to produce drug-loaded implants, personalized dosage forms, micro-scale delivery devices, and precision molds(18,26,27). Major challenges include limited biocompatible resin availability, risk of drug degradation by UV exposure, and the need for post-processing to remove uncured resin(26,27).

❖ **Key Feature**

- Laser-based curing
- High resolution (25–100 µm)
- Very smooth surface finish
- Ideal for precise drug-delivery structures(8,18,25,26,27)

2. Digital Light Processing (DLP) :-

Digital Light Processing (DLP) is another vat-photopolymerization technique, but instead of a laser, it uses a digital projector containing a Digital Micromirror Device (DMD) to cure entire layers of resin at once(28,29,31). The projector flashes a 2D pattern of the sliced layer onto the resin surface, causing instantaneous layer-wide photopolymerization(28,30). Because whole layers are cured simultaneously, DLP is faster than SLA(29,31).

DLP provides extremely high precision because resolution is determined by the projector's pixel size(28,29). It is widely used in pharmaceuticals to create tablets, micro-channels, personalized dosage forms, and fast prototype devices(30,31,32). Limitations include light- induced drug degradation, restricted pharmaceutical-grade resins, and dependence on optical resolution(31,32).

❖ **Key Features**

- Cures full layer at once
- Faster than SLA
- Pixel-based resolution (10–50 µm)
- Useful for rapid pharmaceutical manufacturing(28,29,30,31,32)



Figure 4:- Digital Light Processing(DLP)(34)

3.SELECTIVE LASER SINTERING(SLS):

Selective Laser Sintering (SLS) is a powder-bed fusion 3D-printing technology in which a high-powered laser selectively fuses polymer, metal, or ceramic powder particles to form a solid 3D object(2,35).

❖ **Working Principle**

1. Powder Deposition
   A thin layer of powder (e.g., nylon, PVP, PLA, metal alloys) is spread across the build platform using a roller or blade(2,36).
2. Selective Laser Exposure
   A CO_2 or fiber laser scans the cross-section of the digital 3D model and locally heats the particles, causing them to sinter (partially melt and fuse)(35,37).
3. Layer-by-Layer Building
   After sintering one layer, the platform moves downward and a new powder layer is spread. The laser again fuses particles according to the next layer(2,35).
4. Self-Supporting Powder Bed
   Unfused powder surrounds the part, eliminating the need for support structures, making SLS suitable for complex or hollow geometries(2,37).
5. Post-Processing
   Excess powder is removed. Additional steps (polishing, surface finishing, sterilization) may be performed for pharmaceutical or biomedical use(36,38).

❖ **Applications in Pharmaceuticals**

- Fabrication of porous drug-delivery systems(Ideal for controlled or delayed-release tablets)(38,39).
- Rapid prototyping of medical devices(Inhalers, dosage measuring tools, implant components)(36,38).
- Customization(Patient-specific implants or braces)(36,39)
- Production of high-strength polymer dosage forms(38).

❖ **Advantages**

- No support structures require(2).
- High mechanical strength(35,37).
- Suitable for complex geometries(2,36).
- Broad material compatibility(36).
- Good for temperature-stable APIs and polymers(38,39).

❖ **Limitations**

- Not suitable for heat-sensitive drugs (due to high laser energy)(39,40).
- Surface finish may be rough(35,37).
- High equipment and material cost(2,35).
- Longer cooling time (powder bed must cool gradually)(37,40).

Figure 5:- Selective Laser Sintering (SLS)(41)



4.INKJET/BINDER JETTING AND DROP-ON-DEMANDS:

1. Inkjet Printing / Binder Jetting (BJ):-

Binder Jetting is an additive manufacturing (AM) process in which a liquid binder is selectively deposited onto a powder bed to bind powder particles and form solid structures layer-by- layer(4).

❖ **Working Principle**

1. A thin layer of powder (drug, polymer, excipient) is spread on the build platform(27).
2. The print head moves over the powder bed(42).
3. Inkjet nozzles eject tiny droplets of liquid binder only where the object should be formed(43).
4. The binder wets the powder and forms solidified regions(27).
5. Another layer of powder is spread, and the process repeats(4).
6. Finally, the loose powder is removed, leaving the printed structure (tablet, porous scaffold, etc.)(11).

❖ **Key Features**

- Suitable for drugs sensitive to heat (since no high temperature is used)(27).
- Capable of high drug loading(46).
- Allows complex shapes and porous tablets (fast-dissolving)(47).

❖ **Applications in Pharmaceutics**

- Fabrication of personalized tablets(27).
- Rapidly disintegrating dosage forms(47).
- Complex internal channels for controlled release(11).
- 3D printed scaffolds for tissue engineering(25).



Figuer 6:- Inkjet Printing / Binder Jetting (BJ)(50)

2. Drop-on-Demand (DOD) Inkjet Printing:-

DOD is a precise droplet-ejection method used in pharmaceutical inkjet printing and binder jetting systems(43).

Unlike continuous inkjet (CIJ), the nozzles eject droplets only when required ("on demand")(48).

❖ **Types of DOD**

1. Thermal DOD

A micro-heater produces a bubble → bubble expansion forces a drop out(48).

2. Piezoelectric DOD

A piezoelectric crystal deforms when voltage is applied → pressure ejects the droplet(49).

Widely used in pharma because it avoids high heat(43).

❖ **Characteristics**

- Very accurate droplet placement (picoliters–nanoliters).
- Suitable for deposition of API solutions, binders, and polymers.
- Allows precise dose adjustment by controlling number of droplets(44).

❖ **Applications in Pharmaceutics**

- Printing drug solutions/suspensions onto substrates.
- Creating personalized-dose oral films.
- Deposition of bio-inks and biological materials.
- Used as the droplet mechanism inside binder-jetting printers(27).



Figure 7:- . Drop-on-Demand (DOD) Inkjet Printing(51)

5.SEMI-SOLID EXTRUSION (SSE)/ PRESSURE-ASSISTED MICROSYRINGE (PAM):

Semi-Solid Extrusion (SSE), also known as Pressure-Assisted Microsyringe (PAM), is an additive manufacturing technique in which a semi-solid material such as a gel, paste, or polymer dispersion is extruded through a nozzle to build structures layer-by-layer (52).

Extrusion is driven by pneumatic pressure or by mechanical actuation of a piston or stepper motor (53).

The deposited material solidifies by mechanisms such as drying, cooling, gelation, or chemical/ionic cross-linking depending on the formulation (54).

❖ **Working Principal**

1. A semi-solid formulation is first prepared by dispersing or dissolving the drug in a polymer gel, paste, or hydrogel matrix (55).
2. The formulation is loaded into a syringe-type barrel or cartridge connected to an extrusion nozzle (56).
3. Controlled pressure forces the material through the nozzle, depositing continuous filaments according to the digital CAD model (57).
4. Successive layers are deposited to build the 3D object with defined geometry and surface characteristics (58).
5. After deposition, the structure undergoes drying, cooling, photo-curing, or ionic cross-linking to achieve mechanical stability (59).

❖ **Advantages**

- SSE operates at room temperature or mild temperatures, making it suitable for thermolabile drugs, peptides, and proteins (60).
- It allows incorporation of high drug loading due to the ability to print viscous semi- solid matrices (61).
- The technique is compatible with a wide range of pharmaceutical materials including hydrogels (alginate, gelatin), cellulosic gels (HPMC, CMC), and rheology-modified pastes (62).
- SSE is ideal for personalized dose printing in pediatrics and geriatrics because dose and geometry can be adjusted digitally (63).

❖ **Limitation**

- Printed products may have lower mechanical strength compared to FDM or SLS and often require post-processing such as drying or cross-linking (64).
- Resolution is lower than photopolymerization methods because filament width depends on nozzle diameter and rheological properties (64).
- Formulation rheology (viscosity, yield stress, thixotropy) strongly influences printability, and improper rheology can cause spreading or nozzle clogging (65).
- Print times can be longer because semi-solid structures require additional setting or drying steps (66).

❖ **Pharmaceutical Applications**

- SSE is used to fabricate orodispersible films and tablets with precise dosing and rapid disintegration.
- Customized oral dosage forms for individualized therapy, including polypills, have been successfully demonstrated using SSE.
- Hydrogel scaffolds and implants for local or sustained drug delivery can be produced using alginate, gelatin, or PEG-based hydrogels.
- SSE enables printing of transdermal systems and microneedle arrays from polymer gel formulations(67).



Figure 8:- Semi-Solid Extrusion(SSE)(52)

6.OTHER EMERGING TECHNIQUES (ELECTROHYDRODYNAMIC,TWO-PHOTON POLYMERIZATION)

1. Electrohydrodynamic (EHD) Printing / Electrohydrodynamic Jetting (E-Jet Printing)

Electrohydrodynamic (EHD) printing is an emerging additive-manufacturing technique in which an electric field is applied to a highly viscous polymer/drug solution to generate ultrafine jets, enabling micro- to nanoscale 3D structures(68,69).

❖ **Working Principle**

1. A syringe filled with polymer/drug solution is connected to a conductive nozzle(68). A high voltage (0.5–5 kV) is applied(69).
2. The electric field causes charge accumulation at the droplet meniscus(71).
3. The droplet elongates into a Taylor cone, producing an extremely thin jet(69).
4. The jet is deposited layer-by-layer onto a collector substrate(68).
5. Very fine patterns (down to sub-micron resolution) can be produced(69).

❖ **Key Features**

- Able to print high-viscosity semisolids and polymer melts(70).
- Fabrication of micro-needles, drug-loaded microstructures, nanofibers, and localized delivery systems(68,70).
- High precision; nozzle diameter much larger than final jet size(71).

❖ **Applications in Pharmaceutics**

- Personalized drug-loaded micro-patches(70).
- Nano-fibrous drug delivery systems(68).
- High-potency drugs requiring ultra-low doses(70).
- Printed microneedles with controlled drug loading(68).



Figure 9 :- Electrohydrodynamic (EHD) Printing(76)

3. Two-Photon Polymerization (2PP) / Two-Photon Lithography (TPL)

Two-photon polymerization is an ultra-high-resolution 3D printing technology in which a focused femtosecond laser simultaneously excites two photons within a photopolymer resin, causing polymerization only at the focal point(72,75).

❖ **Working Principle**

1. A near-infrared femtosecond laser (700–1000 nm) is tightly focused inside a photosensitive resin(73).
2. Polymerization occurs only when two photons are absorbed simultaneously, producing a nonlinear effect(75).
3. Because polymerization is confined to the femtoliter-scale focal volume, 3D nanostructures with ~100 nm or even sub-100 nm resolution can be fabricated(72,73).
4. The laser scans in XYZ to create the object point-by-point(75).

❖ **Key Features**

- Highest resolution among all 3D-printing technologies(73).
- Enables the creation of micro-needles, micro-

containers, micro-robots, and implantable micro-devices for drug delivery(73,74).

- Compatible with biocompatible resins and stimuli-responsive polymers(74).

❖ **Applications in Pharmaceutics**

- High-precision drug-delivery micro-implants(74).
- Porous scaffolds for tissue engineering(73).
- Micro-needles with nanoscale surface modifications(73).
- Encapsulation devices for localized, controlled release(74).



Figure 10 :- Two Photon Polymerization(2PP)(77)

Figure 11:- 3D Oral Solid Dosage Form(83)

PHARMACEUTICAL APPLICATIONS:

1. **Oral solid dosage forms**
   3D printing can fabricate tablets with tailored release through geometry modulation (surface area-to-volume ratio), internal infill patterns, multi-layered shells, and use of functional polymers(78). Immediate release, delayed release, and sustained release profiles have been demonstrated(79).
2. **Polypills and fixed-dose combinations**
   3D printing enables combining multiple active pharmaceutical ingredients (APIs) with distinct release kinetics into a single unit—beneficial for polypharmacy, adherence, and fixed-dose combination therapies(80).
3. **Pediatrics and geriatrics dose personalization**
   On-demand manufacturing enables precise dose adjustments for pediatric or geriatric patients. Patient-specific shapes, tastes (by incorporating flavors), and swallowability improvements (mini-tablets, orodispersible

films) are possible(81).

4. **Implants and scaffolds for local delivery**
   Biodegradable polymer implants and scaffolds can be fabricated to deliver drugs locally over extended periods — useful in oncology, orthopedics, and regenerative medicine(82).
5. **Transdermal and topical dosage forms**
   3D-printed microneedles and structured patches offer controlled transdermal delivery. Microneedle arrays can be printed using SSE or SLA with biocompatible resins or dissolvable polymers(82).
6. **Orally disintegrating films**
   Inkjet printing and SSE have been used to produce films and ODTs with rapid disintegration and precise dosing; these are advantageous for patients with dysphagia(78).
7. **Parenteral devices and microneedles**
   Sterile 3D-printed syringes, customized catheters, and microneedle patches are under investigation; materials must meet stringent biocompatibility and sterilization requirements(82).
8. **Clinical and hospital pharmacy applications (point-of-care)**
   Hospitals and compounding pharmacies can potentially print patient-specific doses on demand, reducing waste and improving adherence(80). This raises questions of operational control, sterility, and regulatory oversight(78).

CHALLENGES AND LIMITATIONS:

1. **Material limitations and biocompatibility**
   Many printing materials were originally developed for engineering rather than pharmaceuticals; regulatory and biocompatibility hurdles remain(78).
2. **Reproducibility and inter-batch variability**
   Small changes in feedstock, environmental conditions, or printer calibration can alter product quality; stringent process controls and validation are essential(84).
3. **Intellectual property and legal considerations**
   Printing of copyrighted designs or patented formulations raises legal queries; companies must plan IP strategies(85).
4. **Cost and access to technology**
   While desktop printers lower barriers to entry, validated pharmaceutical-grade printing and GMP facilities require capital investment and specialized expertise(25).

FUTURE DIRECTIONS AND RESEARCH OPPORTUNITIES:

- Bioprinting and combination products: Printing living tissues or cell-laden constructs with integrated drug delivery(82).
- Smart dosage forms: Incorporation of sensors or responsive materials for on-demand release(82).
- Closed-loop point-of-care manufacturing: Integrating diagnostics with on- site printing for personalized therapy(84).
- Improved excipients and printable APIs: Development of APIs and excipients optimized for AM processes (thermostable, printable formulations)(78).
- Regulatory frameworks and standards: Establishing harmonized guidelines for AM in pharmaceuticals to enable broader clinical adoption(25).

CONCLUSION:

3D printing in pharmaceuticals holds great promise to enable personalized therapies, novel dosage forms, and on-demand manufacturing. Challenges remain in materials science, process validation, regulatory alignment, and economics. With focused research and collaboration between academia, industry, and regulators, AM can move from promising demonstrations toward routine clinical and commercial practice.

REFERENCES:

1. Hull CW. Apparatus for production of three-dimensional objects by stereolithography. U.S. Patent 4,575,330 (1986).
2. Gibson I, Rosen D, Stucker B. Additive Manufacturing Technologies. Springer; 2015.
3. Lipson H, Kurman M. Fabricated: The New World of 3D Printing. Wiley; 2013.
4. Katstra WE, Rowe CW, et al. Oral dosage forms fabricated by 3D printing. Pharm Res. 2000;17(10):1206-1212.
5. Rowe CW, et al. Printing of drug delivery devices. J Control Release. 2000;66(1):11-17.
6. Norman J, Madurawe RD, et al. A review of 3D printing technologies for pharmaceutical applications. J Pharm Sci. 2017;106(1):1-17.
7. Alhnan MA, et al. Emergence of 3D-printed dosage forms. Pharm Res. 2016;33(8):1817-1832.
8. Melocchi A, et al. 3D printing in pharmaceutics: materials and technologies. Adv Drug Deliv Rev. 2020;153:116-143.
9. ASTM International. ASTM F2792 – Standard Terminology for Additive Manufacturing Technologies. ASTM; 2012.
10. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372:793-795.
11. Awad A, Trenfield SJ, et al. 3D printing in

personalized medicine. Adv Drug Deliv Rev. 2021;173:310-331.
12. UK Government. Genome UK: The Future of Healthcare. 2020.13. Prasad LK, Smyth H. 3D printing technologies in personalized drug delivery. Drug Dev Ind Pharm. 2020;46(9):1443-1456
13. Prasad, L. K., & Smyth, H. (2020). 3D printing technologies and their role in pharmaceutical development. Drug Development and Industrial Pharmacy, 46(9), 1443–1456.
14. U.S. Food and Drug Administration (FDA). (2015). FDA approves the first 3D printed drug.
15. Prasad LK, Smyth H. "3D Printing technologies for drug delivery applications." Drug Dev Ind Pharm, 2016.
16. Konta A, García-Piña M, Serrano DR. "Personalised 3D printed medicines: principles and current applications." Int J Pharm, 2020.
17. Sadia M et al. "Adaptation of pharmaceutical excipients to FDM 3D printing for drug delivery." Eur J Pharm Biopharm, 2018.
18. Jamróz W, Szafraniec J, Kurek M, Jachowicz R. "3D printing in pharmaceutical and medical applications." Pharm Res, 2018.
19. Park B et al. "3D printing of oral solid dosage forms." J Pharm Sci, 2019.
20. A. Melocchi et al., "Fused deposition modeling (FDM) technique for the production of oral drug delivery systems," International Journal of Pharmaceutics, 2016.
21. M. A. Goyanes et al., "3D printing of modified-release oral tablets using FDM," Journal of Controlled Release, 2015.
22. Z. R. Alqahtani et al., "Pharmaceutical applications of fused deposition modeling (FDM) 3D printing," Pharmaceutics, 2021.
23. G. K. Eleftheriadis & D. Fatouros, "3D printing applications in pharmaceutical formulation and drug delivery," Pharmaceutics, 2020.
24. Sadia et al., "Hot-melt extrusion and FDM: a new tool for personalized medicines," Advanced Drug Delivery Reviews, 2018.
25. Ventola, C. L. "Medical Applications of 3D Printing." P&T, 2014.
26. Konta, A. et al., "3D printing for drug delivery: technologies and challenges." Drug Discovery Today, 2017.
27. Goyanes, A. et al. "Stereolithography for pharmaceutical applications." International Journal of Pharmaceutics, 2015.
28. Robles-Martinez, P. et al. Additive Manufacturing, 2020.
29. Gross, B. C. et al. "Evaluation of 3D printing technologies." Journal of Materials Processing Technology, 2014.
30. Wang, J. et al. "Pharmaceutical 3D printing." Journal of Pharmaceutical Sciences, 2017.
31. Elbadawi, M. et al. "DLP 3D printing for pharmaceuticals." International Journal of Pharmaceutics, 2020.
32. Martinez, P. R. et al. "Photopolymer systems for drug delivery." Advanced Drug Delivery Reviews, 2021.
33. JOURNAL OF MECHANICS OF CONTINUA AND MATHEMATICAL SCIENCES
34. Progress in Additive Manufacturing
35. Deckard, C. R. Selective Laser Sintering (SLS) Technology. University of Texas at Austin, 1989.
36. Awad, A., Fina, F., Goyanes, A., et al. "3D Printing: Principles and Pharmaceutical Applications." International Journal of Pharmaceutics, 2017.
37. Campbell, I., Bourell, D., & Gibson, I. "Additive Manufacturing: Rapid Prototyping Comes of Age." Rapid Prototyping Journal, 2012.
38. Nayak, A., & Goel, H. "Selective Laser Sintering in Pharmaceutical Product Development." European Journal of Pharmaceutical Sciences, 2018.
39. Trenfield, S. J., Awad, A., Goyanes, A., et al. "Pharmaceutical Applications of SLS 3D Printing." International Journal of Pharmaceutics, 2019.
40. Fina, F., Goyanes, A., Rowland, M., et al. "Engineering Drug Release Profiles Using SLS 3D Printing." Eur. J. Pharmaceutics & Biopharmaceutics, 2018.
41. https://5.imimg.com/data5/XB/YE/RX/SELLER-51687494/selective-laser-sintering- service-1000x1000.jpg
42. ISO/ASTM 52900 (2021). Additive manufacturing — General principles — Terminology (Binder Jetting Section).
43. Hsiao, W. K., Lorber, B., Reitsamer, H., & Khinast, J. G. (2010). "Inkjet printing of pharmaceuticals." Journal of Pharmaceutical Sciences, 99(8), 3464–3475.
44. Wu, C. Y., & Yang, X. (2018). "Research advances in Drop-on-Demand inkjet printing for drug delivery." Advanced Drug Delivery Reviews, 132, 104–114.
45. Book: "Inkjet Technology for Digital Fabrication" (Ed. Ian M. Hutchings & Graham D. Martin, 2012).
46. Rowe et al.,2012,Handbook of Pharmaceutical Excipients
47. Skowyra et al.,2015,International Journal of

Pharmaceutics
48. Hutchings & Martin, 2012, Inkjet Technology for Digital Fabrication.
49. Derby, 2010, Annual Review of Materials Research.
50. https://www.researchgate.net/publication/379151302/figure/fig16/AS:11431281280353849@1727376156561/Schematic-diagram-of-binder-jetting-BJ.png
51. https://www.researchgate.net/publication/340675351/figure/fig1/AS:11431281119137782@1676024183702/Schematic-illustration-of-drop-on-demand-inkjet-printing-process-a-piezoelectric-DOD.ppm
52. Goyanes, A., et al. International Journal of Pharmaceutics, 2019 – Review of SSE 3D printing.
53. Jamróz, W., et al. Journal of Controlled Release, 2018 – PAM mechanism in pharmaceutical printing.
54. Araújo, M., et al. Materials Science and Engineering C, 2020 – Solidification mechanisms in SSE.
55. Khaled, S.A., et al. International Journal of Pharmaceutics, 2015 – Formulation preparation for SSE.
56. Trenfield, S.J., et al. Pharmaceutics, 2018 – Cartridge and microsyringe systems.
57. Seoane-Viaño, I., et al. Advanced Drug Delivery Reviews, 2021 – Controlled extrusion in SSE 3D printing.
58. Goyanes, A., et al. Additive Manufacturing, 2018 – Layer-by-layer construction in SSE.
59. Araújo, M. & Serra, A. Materials Science & Engineering C, 2020 – Post-processing and curing.
60. Jamróz, W., et al. Pharmaceutical Research, 2017 – Low-temperature benefits.
61. Khaled, S.A., Burley, J.C., et al. International Journal of Pharmaceutics, 2015 – High drug loading in SSE.
62. Seoane-Viaño, I., et al. Journal of Pharmaceutical Sciences, 2020 – Material compatibility.
63. Goyanes, A., et al. Pharmaceutics, 2020 – Personalised dosing with SSE.
64. Trenfield, S.J., et al. 3D Printing in Medicine, 2019 – Mechanical limitations.
65. Jamróz, W., et al. European Journal of Pharmaceutical Sciences, 2017 – Resolution limits.
66. Araújo, M., et al. Drug Development and Industrial Pharmacy, 2020 – Rheology and printability.
67. Seoane-Viaño, I., et al. Advanced Drug Delivery Reviews, 2021 – Time and drying limitations.
68. Cho, S. et al. (2019). Electrohydrodynamic jet printing for pharmaceutical micro- fabrication. Advanced Drug Delivery Reviews, 146, 37–52.
69. Park, J. U. et al. (2007). High-resolution EHD printing of polymer inks. Nature Materials, 6, 782–789.
70. Raut, S. et al. (2023). Emerging EHD-based 3D printing for controlled drug delivery. International Journal of Pharmaceutics, 631, 122571.
71. Onses, M. S. et al. (2015). Mechanisms of nanostructure formation in E-jet printing. Advanced Materials, 27, 693–705.
72. Maruo, S., Nakamura, O., & Kawata, S. (1997). Three-dimensional microfabrication using two-photon-absorbed photopolymerization. Optics Letters, 22(2), 132–134.
73. Malinauskas, M. et al. (2013). 3D micro- and nano-structuring via 2PP for biomedical applications. Laser & Photonics Reviews, 7(5), 681–711.
74. Kumi, G. et al. (2010). 2PP for rapid microfabrication of biodegradable medical devices. Advanced Materials, 22(9), 929–932.
75. Farsari, M. & Chichkov, B. N. (2009). 2PP microfabrication for bio-applications. Nature Photonics, 3, 450–452.
76. Su, S.; Liang, J.; Wang, Z.; Xin, W.; Li, X.; Wang, D. Microtip focused electrohydrodynamic jet printing with nanoscale resolution. Nanoscale, 2020, 12, 24450– 24462. DOI: 10.1039/D0NR08236H
77. https://ars.els-cdn.com/content/image/1-s2.0-S2214860423000878-gr1.jpg
78. Melocchi, A., et al. (2020). 3D printing in oral drug delivery. Advanced Drug Delivery Reviews, 159, 28–48.
79. Aprecia Pharmaceuticals. (2015). FDA approval of Spritam® — first 3D-printed drug.
80. Khaled, S. A., et al. (2014). 3D printing of a five-in-one polypill. Journal of Controlled Release, 217, 308–314.
81. Goyanes, A., et al. (2014). 3D printing of personalized pediatric doses. International Journal of Pharmaceutics, 476, 88–92.
82. Chia, H. N., & Wu, B. M. (2015). Recent advances in 3D printing of biomaterials. Journal of Biological Engineering, 9, 4.
83. https://www.google.com/url?sa=i&url=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs40964-020-00127-5&psig=AOvVaw3ovefwlNGmef_q2k8mzk_3&ust=1764002855024000&source=images&cd=vfe&opi=89978449&ved=0CBUQjRxqFwoTCPDLpfPciJEDFQAAAAAdAAAAABAE

84. Awad, A., et al. (2021). 3D printing at point-of-care. Drug Discovery Today, 26, 53–64.
85. Tappa, K., & Jammalamadaka, U. (2018). 3D printing in clinical medicine. Materials Today, 21, 746–756.